Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q2 & H1 FY26 Earnings Presentation
31 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, Nov 12, 2025
Slide 1: Exchange filing cover letter
12th November 2025 IOLCP/CGC/2025 National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Investor Presenta
Slide 2: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q2 & H1 FY26
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q2 & H1 FY26
Slide 3: Q2 & H1 FY26 Performance
Q2 & H1 FY26 Performance
Slide 4: Business Updates
Business Updates CEP Certification • EDQM issued a Certificate of Suitability (CEP) for Pantoprazole Sodium for Pantoprazole Sesquihydrate Process-III on 14th October 2025, enabling exports to Europe and other CEP-compliant markets Sodium • Pantoprazole sodium is a proton pump inhibitor (PPI) that r
Slide 5: Q2 & H1 FY26 Standalone Performance Highlights
Q2 & H1 FY26 Standalone Performance Highlights Q2 FY26 ₹ 567.5 Cr ₹ 30.0 Cr ₹ 64.0 Cr Revenue from Operations Profit After Tax EBITDA 7.9% YoY 33.3% YoY 56.7% YoY EBITDA Margin 11.1% PAT Margin 5.2% H1 FY26 ₹ 1,119.2 Cr ₹ 133.5 Cr ₹ 64.0 Cr Revenue from Operations EBITDA Profit After Tax 8.9% YoY 25
Slide 6: Q2 & H1 FY26 Standalone Performance Highlights
Q2 & H1 FY26 Standalone Performance Highlights Pharmaceuticals Chemicals Geographical Break-up (In ₹ Cr) (In ₹ Cr) 231.9 24% 665.7 329.3 336.4 438.7 453.5 222.4 231.2 589.5 293.8 75.5 40.1 76% 59.2 24.6 35.5 4.2 11.0 1.9 5.9 5.1 H1 FY25 H1 FY26 Q2 FY25 Q1 FY26 Q2 FY26 H1 FY25 H1 FY26 Q2 FY25 Q1 FY26
Slide 7: Standalone Profit & Loss Statement – Q2 & H1 FY26
Standalone Profit & Loss Statement – Q2 & H1 FY26 Particulars (in INR Cr.) Q2 FY26 Q2 FY25 Y-o-Y Q1 FY26 Q-o-Q H1 FY26 H1 FY5 Y-o-Y Revenue from Operations 567.5 525.8 7.9% 551.7 2.9% 1,119.2 1,028.1 8.9% Other Income 6.9 6.4 7.4 14.3 13.8 Total Revenue 574.4 532.2 7.9% 559.1 2.7% 1,133.5 1,041.9 8.
Slide 8: Standalone Balance Sheet
Standalone Balance Sheet Particulars (in INR Cr.) Sep 25 Mar 25 Particulars (in INR Cr.) Sep 25 Mar 25 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,127.9 1158.0 (i) Equity share capital 58.7 58.7 (ii) Right to Use Asset (ii) Other equity 1,692.4 1628.7
Slide 9: Standalone Cash Flow Statement
Standalone Cash Flow Statement Particulars (in INR Cr.) Sep 25 Sep 24 Cash Flow from Operating Activities Profit before Tax 86.1 65.2 Adjustment for Non-Operating Items 41.1 37.5 Operating Profit before Working Capital Changes 127.1 102.6 Changes in Working Capital -100.1 -89.6 Cash Generated from O
Slide 10: At a Glance
At a Glance
Slide 11: Journey So Far
Journey So Far 1986-91 1996-99 2000-07 2009-13 2015-16 2017-18 2019 - 20 2021-22 2023 2024 2025 • 1986: • 2000 - Commencement of • 2015 - USFDA, EIR for • 2019 - Unit-06 for • Paracetamol capacity has • Commencement Incorporation of Ibuprofen Unit-1 Ibuprofen Pantoprazole (Dedicated) been increased
Slide 12: Business Overview
Business Overview Team size of 3000+ Among the top global Existing Facility: Zero Discharge Largest producer of employees producers of Iso Butyl Spanning 180+ acres Effluent Treatment Ibuprofen and the only Benzene (IBB) Plant company worldwide being Expansion: Acquired 101 fully backward integrated
Slide 13: Segment Overview- Pharmaceuticals
Segment Overview- Pharmaceuticals World’s only company with complete backward Commenced a fully backward-integrated Unit-11 Largest global producer of Ibuprofen, with an annual integration for Paracetamol manufacturing at Barnala, with an capacity of 12,000 MT installed capacity of 10,800 MTPA The s
Slide 14: Segment Overview- Specialty Chemicals
Segment Overview- Specialty Chemicals Producing Acetic Anhydride Asia’s first continuous dual REACH-certified for Ethyl Among the largest global Ethyl Acetate with capacity of 25,000 technology plant for MCA Acetate & Acetic Anhydride, manufacturers of Iso Butyl manufacturing capacity of MTPA - for
Slide 15: Pharmaceuticals- A Key Focus
Pharmaceuticals- A Key Focus Expanding the non-Ibuprofen Business Installed Capacity Regulatory Filings* Therapeutic Area USDMF, CEP & ANVISA GMP Metformin Hydrochloride 7200 MTPA Anti-Diabetic Approved, China DMF Active 59% 58% USDMF, CEP & ANVISA GMP 57% Fenofibrate Multiproduct Plant Anti-Cholest
Slide 16: Manufacturing Facilities
Manufacturing Facilities API manufactured in batch manner and intermediates Facility is coupled with ISO class-8 HVAC system, PSA Dedicated and multiproduct blocks involved in & Specialty chemicals in continuous product delivery Nitrogen & Purified water along with 185 MTPH steam manufacturing of AP
Slide 17: Research & Development
Research & Development From Lab to Launch: 20 Products Commercialized, 9 More in Pipeline — R&D at the Heart of Our Growth Story 3 15 20 Patents DMFs with USFDA CEPs with EDQM (18 Approved, 2 Under Review) A 120-member highly Working on generic skilled team, including 50+ molecules with latest DSIR
Slide 18: Certifications & Accreditations
Certifications & Accreditations Approved USFDA facility since EUGMP Certification in 2013, 2017 Certificate of Suitability Certified Halal in accordance with Certificate of DMF Registration ISO 9001:2015, 14001:2015 & 2015, recertified in 2019 & Recertification in 2020 from EDQM Shariah Board Guidel
Slide 19: Core Management Team
Core Management Team Varinder Gupta | (Managing Director) Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence. Vikas Gupta | (Joint Managing
Slide 20: Board of Directors
Board of Directors Rajender Mohan Malla Sharad Tyagi Harpal Singh Ms Rajni Jha (Chairman and Independent (Independent Director) (Independent Director) (Independent Director) Director) o With four decades of experience held o Over 38 years of intrapreneurship in o Over 37 year's experience of banking
Slide 21: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Awarded EcoVadis Silver Medal recognizing strong ESG Performance & Global Sustainability Leadership; Ranks Among the Top 15% companies globally o Committed to becoming carbon neutral by 2050 o 100 % State of the art Zero liquid Discharge (ZLD)
Slide 22: Industry Overview
Industry Overview
Slide 23: API Industry- Overview
API Industry- Overview Global API Market Size (In USD Bn) Indian API Market Size (In USD Bn) 4.40% 368.98 38.60 8.10% North America holds over 38% of India is the 3rd largest API the API market in 2024. 245.59 producer globally, contributing 8% Asia-Pacific—led by India and to the market, with over
Slide 24: Specialty Chemicals Industry- Overview
Specialty Chemicals Industry- Overview Global Spec. Chem Market Size Indian Spec. Chem Market Size Region wise Spec. Chem Market Size Growth (FY25-30) (In USD Bn) (In USD Bn) 3.23% 11% 3.80% 1054.70 92.60 7% 780.30 64.50 4% 3 3% 3% 2% 2024 2033 2024 2034 North Latin Europe Middle Japan China India A
Slide 25: Historical Performance
Historical Performance
Slide 26: Historical Standalone Performance
Historical Standalone Performance Revenues EBITDA & EBITDA % Cash Profit After Tax 13.0% 11.2% 12.1% 10.7% 2216 2243 2163 2102 288 209 208 252 262 189 185 225 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Segmental Revenue Cash Flow from Operations Capex Spent 1175 1259 1263 1212 290 2
Slide 27: Summary Statement of Standalone Profit and Loss
Summary Statement of Standalone Profit and Loss Particulars (in INR Cr.) FY25 FY24 FY23 FY22 Revenue from Operations 2079.2 2,132.8 2,217.1 2,184.0 Other Income 22.4 30.1 25.6 32.0 Total Revenue 2101.6 2,162.9 2,242.7 2,216.1 Cost of Materials Consumed 1358.3 1,435.1 1,536.1 1,578.9 Purchase of Trad
Slide 28: Summary Statement of Standalone Balance Sheet
Summary Statement of Standalone Balance Sheet Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,158.0 921.1 750.5 559.5 58.7 58.7 58.7 58.7 (i) Equity s
Slide 29: Summary Statement of Standalone Cashflow
Summary Statement of Standalone Cashflow Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 Cash Flow from Operating Activities Profit before Tax 137.9 182.6 189.5 222.8 Adjustment for Non-Operating Items 79.8 59.8 44.4 33.1 Operating Profit before Working Capital Changes 217.7 242.4 233.9 256.0 C
Slide 30: Way Forward
Way Forward Backward Integration for Margin Product Diversification Beyond Export Contribution to Rise Scaling Through Land Acquisition and Supply Chain Resilience Ibuprofen The non-Ibuprofen share in the pharmaceuticals segment has The company adopts a strategic The company has acquired 101 acres i
Slide 31: Thank You
COMPANY : IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Mr. Abhay Raj Singh - Sr. VP & Company Secretary investor@iolcp.com E-mail: investor@iolcp.com www.iolcp.com www.iolcp.com INVESTOR RELATIONS ADVISORS : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a
IOL Chemicals and Pharmaceuticals — Q2 & H1 FY26 Earnings Presentation on 6ix